Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional Methotrexate for Nail Psoriasis
NCT06578728Phase 4Terminated
- Sponsor
- Weill Cornell Medicine
- Start
- Sep 2025
- Primary completion
- Jun 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised trial of methotrexate in nail psoriasis (3 arms), sponsored by Weill Cornell Medicine. Primary endpoints: Nail Psoriasis Severity Index at week 37 and Physician-Assessed Global Improvement at week 37. Started Sep 2025; status: terminated.
02
Drugs
methotrexate
03
Conditions
nail psoriasis
Beyond the preview
Go deeper on NCT06578728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06578728.